Comparison of a therapeutic‐only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders
Information
- DOI:
- https://doi.org/10.1002/14651858.CD012342.pub2Copy DOI
- Database:
-
- Cochrane Database of Systematic Reviews
- Version published:
-
- 14 May 2018see what's new
- Type:
-
- Intervention
- Stage:
-
- Review
- Cochrane Editorial Group:
-
Cochrane Haematology Group
- Copyright:
-
- Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Article metrics
Altmetric:
Cited by:
Authors
Contributions of authors
-
Reem Malouf: protocol and review development, searching, selection of studies, eligibility and quality assessment, and data extraction.
-
Asma Ashraf: protocol and review development, searching, selection of studies.
-
Andreas Hadjinicolaou: protocol and review development, searching, selection of studies.
-
Carolyn Doree: protocol and review development and search specialist.
-
Sally Hopewell: protocol and review development and methodological expert.
-
Lise Estcourt: protocol and review development, searching, selection of studies, eligibility and quality assessment, data extraction, and content expert.
Sources of support
Internal sources
-
NHS Blood and Transplant, Research and Development, UK.
To fund the work of the Systematic Review Initiative (SRI)
External sources
-
National Institute for Health Research (NIHR) Cochrane Programme Grant, UK.
To provide funding for systematic reviewers and methodological support from the Centre for Statistics in Medicine, Oxford
Declarations of interest
Reem Malouf: partly funded by the NIHR Cochrane Programme Grant ‐ Safe and Appropriate Use of Blood Components.
Asma Ashraf: none to declare.
Andreas Hadjinicolaou: none to declare.
Carolyn Doree: none to declare.
Sally Hopewell: partly funded by the NIHR Cochrane Programme Grant ‐ Safe and Appropriate Use of Blood Components.
Lise Estcourt: partly funded by the NIHR Cochrane Programme Grant ‐ Safe and Appropriate Use of Blood Components.
Acknowledgements
We thank the editorial base of the Cochrane Haematological Malignancies Review Group.
We thank NHS Blood and Transplant (NHSBT).
We thank the National Institute of Health Research (NIHR). This review is part of a series of reviews that have been funded by the NIHR Cochrane Programme Grant ‐ Safe and Appropriate Use of Blood Components. This research was also supported by the NIHR Oxford Biomedical Research Centre Programme. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service (NHS), or the Department of Health.
We thank Marialena Trivella, who was an author of the protocol.
Version history
| Published | Title | Stage | Authors | Version |
| 2018 May 14 | Comparison of a therapeutic‐only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders | Review | Reem Malouf, Asma Ashraf, Andreas V Hadjinicolaou, Carolyn Doree, Sally Hopewell, Lise J Estcourt | |
| 2016 Sep 01 | Comparison of a therapeutic‐only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders | Protocol | Asma Ashraf, Andreas V Hadjinicolaou, Carolyn Doree, Sally Hopewell, Marialena Trivella, Lise J Estcourt | |
Differences between protocol and review
There were no changes between the protocol, Ashraf 2016, and the completed review. However, many aspects of the review could not be implemented due to the fact that we identified only a single study for inclusion with no actual data. We were unable to perform the following.
-
Completed randomised controlled trials with sufficient data: one trial found with no data.
-
Including non‐randomised trials: we did not identify any non‐randomised trials that fulfilled the inclusion criteria of the review.
-
Primary outcome: we were unable to report on any of the primary outcomes of the review.
-
Secondary outcomes: we were unable to report on any of the secondary outcomes of the review.
-
'Summary of findings' table: we were unable to apply the GRADE tool to rate the quality of evidence for the key outcomes of the review. Consequently, we were unable to create a 'Summary of findings' table for the outcomes prespecified in the protocol: number of participants with at least one bleeding episode; total number of bleeding episodes per participant; number of participants with at least one severe or life‐threatening bleeding episode; all‐cause mortality; number of units of platelet transfusion per participant; quality of life; and transfusion‐related adverse events.
-
Data synthesis: we were unable to conduct any form of data synthesis, i.e. narrative analysis as well as meta‐analysis, for any of the outcomes of the review.
-
Subgroup analysis: we were unable to perform any of the subgroup analyses prespecified in the review protocol.
-
Assessment of heterogeneity: this was not possible due to insufficient studies included in the review.
-
Publication bias: we were unable to examine publication bias via completing the funnel plot because only one trial was included in the review.
Notes
Glossary
Allogeneic: the cells (blood cells or stem cells) come from someone other than the patient.
Cytopenia: the reduction of one or more blood cell types.
Dysplasia: defects in stem cells can cause blood cells to have an abnormal shape or size.
Haematopoiesis: the production of red blood cells, white blood cells, and platelets from stem cells within the bone marrow.
Keywords
MeSH
Medical Subject Headings (MeSH) Keywords
Medical Subject Headings Check Words
Adult; Humans;
PICOs
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
